Bioactive parstatin peptides and methods of use
View Patent ↗Bioactive peptides that have a molecular weight of approximately 4.5 kDa and correspond to amino-terminal fragments of protease-activated receptor-1 (PAR-1), which are cleaved and released upon the proteolytic activation of PAR-1 by proteases including, but not limited to, thrombin in humans and animals are disclosed. Such synthetic or recombinantly expressed or endogenously produced or chimeric synthetic peptides that are active in vitro and in vivo and modulate endothelial cell functions and physiological and pathological processes are named herein as parstatin. Parstatin peptides, fragments, analogs, derivatives have the ability to inhibit endothelial cell growth, migration and differentiation, to induce endothelial cell apoptosis, to block angiogenesis and have cardioprotective effects in ischemia/reperfusion injury. Methods for treating angiogenesis-related diseases and endothelium dysfunction-related cardiovascular diseases are disclosed.
1. A method of inhibiting endothelial cell growth in a mammal comprising:
selecting the mammal as having an angiogenesis-related disease selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, macular degeneration, chronic inflammation, arthritis, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, psoriasis, cancer, atheroschlerosis, intimal hyperplasia, and pulmonary hypertension; and
administering to the mammal a composition comprising a parstatin peptide consisting of SEQ ID NO: 1, thereby inhibiting endothelial cell growth in the mammal.
2. The method of claim 1 , wherein inhibition of endothelial cell growth comprises at least one of inhibition endothelial cell proliferation, inhibition of DNA synthesis, and inhibition of mitogenic intracellular biochemical pathways as compared to endothelial cells not treated with SEQ ID NO: 1.
3. The method of claim 1 , wherein inhibition of endothelial cell growth comprises inhibition of angiogenesis.
4. The method of claim 3 , wherein inhibition of angiogenesis comprises inhibition of at least one of endothelial cell growth, endothelial cell migration, endothelial cell differentiation, and endothelial cell vascular-like tube formation as compared to endothelial cells not treated with SEQ ID NO: 1.
5. A method of inhibiting angiogenesis in a mammal comprising:
selecting the mammal as having an angiogenesis-related disease selected from the group consisting of: diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, macular degeneration, chronic inflammation, arthritis, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, psoriasis, cancer, atheroschlerosis, intimal hyperplasia, and pulmonary hypertension; and
administering to the mammal a composition comprising a parstatin peptide consisting of SEQ ID NO: 1, thereby inhibiting angiogenesis.
6. The method of claim 1 , wherein inhibition of cell growth comprises induction of apoptosis or cell cycle arrest as compared to endothelial cells not treated with SEQ ID NO: 1.
7. The method of claim 1 , further comprising monitoring the mammal for inhibition of endothelial cell growth.
8. A method of treating an ischemia/reperfusion injury in mammalian myocardium comprising:
selecting a mammal for treatment of the ischemia/reperfusion injury; and
administering to the mammal a composition comprising a parstatin peptide consisting of SEQ ID NO: 1, thereby treating the ischemia/reperfusion injury in the mammal.
9. The method of claim 8 , further comprising monitoring the mammal for prevention, amelioration, or treatment of ischemia/reperfusion injury.
10. A method for inhibiting angiogenesis in a mammal comprising:
selecting the mammal as having an angiogenic sprout; and
administering to the angiogenic sprout of the mammal in need thereof a composition comprising a parstatin peptide consisting of SEQ ID NO: 1, thereby inhibiting angiogenesis in the mammal.
11. The method of claim 1 , wherein the mammal is a human.
12. The method of claim 8 , wherein the mammal is a human.
13. The method of claim 10 , wherein the mammal is a human.
14. The method of claim 5 , wherein the mammal is a human.